Skip to content

Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty

Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07073937
Enrollment
100
Registered
2025-07-20
Start date
2025-08-01
Completion date
2026-11-04
Last updated
2026-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Open Angle, MIGS, Minimally Invasive Glaucoma Surgery, Canaloplasty, Intraocular Pressure (IOP), Cataract Surgery, Surgical Technique, Minimally Invasive Surgical Technique, Glaucoma

Brief summary

The goal of this study is to learn if combining minimally invasive glaucoma surgery (MIGS) procedures with different mechanisms of action increases the effectiveness of MIGS. The main question the study aims to answer is: Does combining viscodilation (a surgical technique, often used in glaucoma treatment, that involves using a high-viscosity, elastic gel to widen and open the Schlemm's canal, a main drainage channel in the eye) with the iTrack catheter, along with the Hydrus microstent, show better reduction in intraocular pressure than cataract surgery alone? Researchers will retrospectively review charts of patients who have open-angle glaucoma who have undergone combination Hydrus implantation and 360-degree iTrack canaloplasty with concomitant cataract surgery, who have at least 36 months of clinical follow-up data. Baseline demographic information and severity of glaucoma will be recorded, as will change from baseline yearly to three years in average optical coherence tomography (OCT) retina nerve fiber layer (RNFL) measurements and visual field (VF) pattern standard deviation. Safety outcomes and the percentage of eyes requiring secondary surgical intervention will be recorded at yearly time points.

Interventions

Retrospective study; a total of approximately 100 subjects have been identified to have had minimum 36 months follow-up.

Sponsors

Alcon Research
CollaboratorINDUSTRY
University of Utah
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with open angle glaucoma (mild, moderate or severe as defined below) who have undergone combined Hydrus and 360 degree canaloplasty with concomitant cataract surgery with at least 3-year follow-up data * Mild: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma and a normal visual field as tested with standard automated perimetry (SAP) * Moderate: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma, and visual field abnormalities in one hemifield that are not within 5 degrees of fixation as tested with SAP * Severe: Definite optic disc, RNFL, or macular imaging abnormalities consistent with glaucoma, and visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with standard automated perimetry (SAP) * Patients who have had prior selective laser trabeculoplasty (SLT) are allowed

Exclusion criteria

* Prior corneal graft (penetrating Keratoplasty \[PKP\], deep anterior lamellar keratoplasty \[DALK\], Descemet's Stripping Automated Endothelial Keratoplasty \[DSAEK\], Descemet membrane endothelial keratoplasty \[DMEK\]) & refractive surgery * Prior retinal surgery * Prior MIGS or incisional glaucoma surgery * Angle closure glaucoma and other secondary glaucoma

Design outcomes

Primary

MeasureTime frameDescription
Percentage of surgical success at three years.From baseline to three years post-surgerySurgical success is defined as a decrease of one or more glaucoma medications from baseline without an increase in medicated intraocular pressure (IOP).

Secondary

MeasureTime frameDescription
Mean number of medication reduction from baseline to three yearsFrom baseline to three years post-surgeryMean number of medications the patient has been able to stop taking since baseline
Percentage of eyes with greater than twenty percent reduction in IOP from baseline to year threeFrom baseline to three years post-surgery
Percentage of eyes that are medication free at three yearsAt three years post-surgeryPercentage of eyes that do not need any IOP lowering medication at three years
Mean decrease in IOP from baseline at three yearsFrom baseline to three years post-surgery
Change in average RNFL from baseline yearly to three yearsAt baseline, one year, two years and three years post-surgeryChange from baseline yearly to three years in average optical coherence tomography retina nerve fiber layer measurements. OCT RNFL analysis is a non-invasive imaging technique that measures the thickness of the RNFL to help diagnose and monitor glaucoma.
Change in average HVF PSD from baseline yearly to three yearsAt baseline, one year, two years and three years post-surgeryChange from baseline yearly to three years in visual field pattern standard deviation. VF PSD is a metric that measures the irregularity of visual field loss.
Percentage of eyes requiring secondary surgical intervention at yearly time pointsAt one year, two years and three years post-surgery
Percentage of eyes with IOP between 14 and 18 mmHg on the same number of medications or fewer at three years post-surgeryAt three years post-surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026